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To further identify amino acid domains involved in
the ligand binding specificity of aIIbb3, chimeras of the
conserved calcium binding domains of aIIb and the a
subunit of the fibronectin receptor a5b1 were con-
structed. Chimeras that replaced all four calcium bind-
ing domains, replaced all but the second calcium bind-
ing domain of aIIb with those of a5, or deleted all four
calcium binding domains were synthesized but not ex-
pressed on the cell surface. Additional chimeras ex-
changed subsets or all of the variant amino acids in the
second calcium binding domain, a region implicated in
ligand binding. Cell surface expression of each second
calcium binding domain mutant complexed with b3 was
observed. Each second calcium binding domain mutant
was able to 1) bind to immobilized fibrinogen, 2) form
fibrinogen-dependent aggregates after treatment with
dithiothreitol, and 3) bind the activation-dependent an-
tibody PAC1 after LIBS 6 treatment. Soluble fibrinogen
binding studies suggested that there were only small
changes in either the Kd or Bmax of any mutant. We
conclude that chimeras of aIIb containing the second
calcium binding domain sequences of a5 are capable of
complexing with b3, that the complexes are expressed on
the cell surface, and that mutant complexes are capable
of binding both immobilized and soluble fibrinogen, sug-
gesting that the second calcium binding domain does
not determine ligand binding specificity.
Integrins function as adhesion receptors that mediate cell-
extracellular matrix, cell-cell, and cell-soluble ligand interac-
tions (1). The platelet integrin aIIbb3 (membrane glycoprotein
IIb-IIIa) functions to mediate platelet-platelet and platelet-
subendothelial matrix interactions through the binding of its
ligands: fibrinogen, von Willebrand factor, thrombospondin,
fibronectin, and vitronectin (2, 3). Although progress has been
made in elucidating ligand structure and potential ligand bind-
ing sites in integrins, questions regarding areas that determine
both ligand binding and ligand binding specificity in aIIbb3
remain. While integrins bind diverse ligands, three themes are
apparent in ligand binding. First, many ligands have an acidic
amino acid, usually aspartic acid, in the recognition sequence
(4, 5). Certain integrins, including aIIbb3 and a5b1, bind ligands
that contain the tripeptide sequence arginine-glycine-aspartic
acid (RGD) (6), while the recognition motif of others is more
varied (7). Second, the ligand recognition sequence is usually a
short peptide presented on an extended loop containing a
b-turn (5). For example, the crystal and NMR structures of the
ligand recognition sequence of fibronectin have been deter-
mined (8, 9), revealing the RGD sequence to be present on an
extended loop with a b-turn. Although not as well defined,
NMR studies have shown that the fibrinogen C-terminal
g-chain peptide assumes a helical conformation in solution
with a b-turn centered at residues 408 and 409 (10, 11). Third,
ligand binding specificity is varied. For example, while a5b1
binds primarily to fibronectin, aIIbb3 is a more promiscuous
receptor and binds to multiple ligands.
Much work has been done to determine areas of aIIbb3 in-
volved in ligand binding. Previous studies have implicated
multiple ligand interaction areas on both subunits, leading to
models in which the ligand binding pocket is proposed to be
formed by amino acids contributed by both subunits (12, 13).
The aIIbb3 complex must undergo a conformational change
before it is capable of high affinity binding of fibrinogen, but the
resting complex is still capable of binding small peptide li-
gands. Site-directed mutagenesis (14), peptide and antibody
inhibition (15–18), chemical cross-linking studies (19), and
analysis of thrombasthenic mutations (20–23) have implicated
two areas of b3, amino acids 109–133 and 212–222, in ligand
binding. Recently, a third area, amino acids 274–368, has been
reported to bind fibrinogen (24).
Multiple areas of aIIb appear to be important in ligand bind-
ing. A recombinant truncated fragment, amino acids 171–464,
has been shown to bind fibrinogen in a calcium-dependent
manner (25), while ligand binding specificity has been localized
to the first 334 amino acids of aIIb using aIIbav chimeras (26).
Site-directed mutagenesis of residues in a predicted b-turn in
the third N-terminal repeat of aIIb, a4, and a5 (amino acids
184–193 of aIIb) has shown the region to be critical for ligand
binding (27, 28). A synthetic peptide corresponding to aIIb-
(656–667) has been demonstrated to bind to soluble fibrinogen,
and both the peptide and antibodies to the peptide inhibit
platelet aggregation (29). Only one area of the aIIbb3 has been
shown to bind the fibrinogen g-chain HHLGGAKQAGDV (H12)
peptide in a calcium-dependent manner. Chemical cross-link-
ing of the H12 peptide followed by proteolysis identified the
second calcium binding domain of aIIb, amino acids 296–314, as
a critical region for binding the fibrinogen carboxyl-terminal
g-chain peptide (30). High affinity binding of the H12 peptide
requires calcium and aIIbb3 to be in the activated conformation
(31). Peptides corresponding to amino acids 296–306 or 300–
312 blocked platelet aggregation and bound directly to fibrin-
ogen. Antibodies against aIIb-(296–306) blocked binding of fi-
brinogen to either the peptide or aIIbb3 (32, 33).
Amino acids 296–312 in aIIb define one of four calcium bind-
ing domains of aIIb. The integrin calcium binding domains are
homologous with the “EF-hand” helix-loop-helix motif found in
calmodulin and other proteins (34, 35). However, integrin cat-
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ion binding domains are missing the flanking helices and one of
six divalent cation coordination sites. These coordination sites
are presented as a linear array of amino acids having precisely
spaced oxygenated side chains at positions 1, 3, 5, 9, and (in
true EF-hands) 12. Position 7 contributes a coordination site
through its main chain carbonyl. The divalent cation binding
domains in integrins are missing the oxygenated, nearly in-
variant, glutamic acid residue at position 12, having a small
hydrophobic residue instead. It has been postulated that the
acidic residue in the ligand contributes the final coordination
site (4) and that the metal ion, the ligand, and the receptor
form a transient ternary complex before the metal ion dissoci-
ates (36). The second calcium binding domain of aIIb and a5
occur in a region of high homology, having 80% sequence iden-
tity over 35 amino acids.
In this paper, we examine the expression, complex forma-
tion, and function of a series of chimeric aIIba5b3 molecules in
which we substituted clusters of the divergent a5 amino acids
into the second calcium binding domain of aIIb. The mutations
were made as chimeras in order to preserve both calcium and
RGD binding, while probing ligand binding specificity. The
results indicate that these mutants are expressed on the cell
surface, complex with b3 but not b1, and function in a manner
indistinguishable from wild type aIIbb3, indicating that the
second calcium binding domain of aIIbb3 does not determine
ligand binding specificity.
EXPERIMENTAL PROCEDURES
Materials—EA.hy 926, an endothelial-adenocarcinoma hybrid cell,
l-gt11 cDNA library was provided by C.-J. Edgell (University of North
Carolina, Chapel Hill, NC) (37). A partial-length aIIb was the gift of M.
Poncz (University of Pennsylvania, Philadelphia, PA). A l-gt11 liver
cDNA library was provided by L. Brass (University of Pennsylvania).
Cloned a5 cDNA was provided by R. Juliano (University of North
Carolina). Bluescript KS was from Stratagene (San Diego, CA). The
plasmids pcDNAI/AMP and pRc/CMV were from Invitrogen (San Diego,
CA). Oligonucleotides were obtained from the University of North Caro-
lina Department of Pathology Oligonucleotide Synthesis Facility. The
T7-GEN In Vitro Mutagenesis Kit was from U. S. Biochemical Corp.
(Cleveland, OH). Horseradish peroxidase-conjugated streptavidin, Li-
pofectAMINE, and tissue culture media and supplements, except for
fetal bovine serum (FBS),1 were from Life Technologies, Inc. FBS was
from either HyClone (Logan, UT) or Irvine Scientific (Santa Clara, CA).
Pefabloc SC was obtained from Roche Molecular Biochemicals. Protein
A-Sepharose, GammaBind Plus Sepharose, and gelatin Sepharose were
from Amersham Pharmacia Biotech. NHS-LC-biotin was obtained from
Pierce. Biotinylated molecular weight markers, gelatin-agarose, and
fluorescein isothiocyanate (FITC)-Celite were from Sigma. The ECL
chemiluminescence detection system was from Amersham Pharmacia
Biotech. Peptides were from the University of North Carolina Protein
Chemistry Laboratory. Purified fibrinogen and fibronectin were the gift
of L. Parise (University of North Carolina). Human fibrinogen, plas-
minogen- and von Willebrand factor-depleted, for soluble fibrinogen
binding studies, was purchased from Enzyme Research Laboratories,
Inc. (South Bend, IN). Chelex 100 was from Bio-Rad. Other reagents
were from standard sources.
Antibodies—The aIIbb3 complex-specific monoclonal antibody (mAb)
AP2 (38) was supplied by T. Kunicki (Scripps Research Institute, La
Jolla, CA). Anti-b3 mAb AP3 (39) and rabbit polyclonal anti-aIIb SEW 8
were provided by P. Newman (Blood Center of Southeastern Wisconsin,
Milwaukee, WI). The mAb Tab (40), specific for aIIb, was provided by R.
McEver (University of Oklahoma Health Sciences Center, Oklahoma
City, OK). The mAbs A2A9 (41), recognizing the aIIbb3 complex, and
B1B5 (42), recognizing an epitope on aIIb, were provided by J. Bennett
(University of Pennsylvania, Philadelphia, PA). The aIIbb3 complex-
specific mAb 10E5 (43) was provided by B. Coller (Albert Einstein
University, New York, NY). The anti-hamster b1 mAb 7E2 (44) was
provided by R. Juliano (University of North Carolina). The mAb LIBS 6,
specific for b3 (45), was provided by M. Ginsberg (Scripps Research
Institute). PAC1 murine IgM (46) was from University of Pennsylvania
Cell Center (Philadelphia, PA). Monoclonal antibodies against syn-
thetic peptides containing the N- and C-terminal fibrinogen Aa RGD
motifs (Aa 87–100 and Aa 566–580, respectively) were provided by Z.
Ruggeri (Scripps Research Institute). Monoclonal antibody 4A5 (47)
against the fibrinogen g-chain H12 sequence was provided by Gary
Matsueda (Bristol-Myers Squibb Pharmaceutical Research Institute,
Princeton, NJ). FITC-conjugated goat anti-mouse IgG F(ab9)2 was from
Fisher. FITC-conjugated rabbit anti-mouse IgM was from Zymed Lab-
oratories Inc. (South San Francisco, CA). FITC-conjugated chicken anti-
human fibrinogen was from Biopool International (Ventura, CA). Nor-
mal mouse serum, goat anti-mouse IgG, goat anti-rabbit IgG,
horseradish peroxidase-goat anti-mouse IgG, horseradish peroxidase-
goat anti-rabbit IgG, and alkaline phosphatase-conjugated goat anti-
rabbit IgG were from Sigma. Primary antibodies were used as either
ascites fluid or as the IgG fraction after purification on either Protein
A-Sepharose or GammaBind Plus Sepharose.
Isolation of aIIb and b3 cDNA Clones—A full-length aIIb cDNA clone
was isolated from a l-gt11 liver cDNA library using restriction frag-
ments of a partial-length aIIb clone as probes. Partial-length cDNA
clones of b3 were isolated from both the liver cDNA library and an
EA.hy 926, endothelial-adenocarcinoma hybrid cell, l-gt11 cDNA li-
brary. All cDNA isolates were subcloned into Bluescript KS. Full-length
b3 was constructed from two partial clones that overlapped at the
internal EcoRI site. The b3 clone isolated had a G2069A mutation
encoding a C655Y substitution. The mutation was repaired by subclon-
ing a SapI–MluI fragment containing the correct sequence from an
EA.hy926 partial clone.
Construction of Mutant aIIb and b3 cDNA Clones—All clones were
constructed using standard mutagenic and subcloning techniques. A
cDNA encoding b3 with a silent mutation destroying the internal EcoRI
site, b3DE, was prepared using the T7-GEN In Vitro Mutagenesis Kit.
Silent mutations in aIIb creating BstBI and NdeI sites at nucleotides
771 and 1411, respectively, were made simultaneously using the dut-,
ung- method (48). This clone, named BN, was used to make IIba5, a
chimeric cDNA where all four calcium binding domains of aIIb were
replaced with the calcium binding domains of a5 (amino acids 230–
436), and DCa, an in-frame deletion of all four calcium binding domains
of aIIb (amino acids 234–438) (Fig. 1A). To construct IIba5, the calcium
binding domains of a5 were amplified by PCR using oligonucleotides
that contained BstBI and NdeI sites, respectively, and that recon-
structed the aIIb sequence from the restriction site up to the start of the
calcium binding domains. DCa was made by annealing oligonucleotides
CGAACCCAGAGTACTTCGACGGCGCA and TATGCGCCGTCGAAG-
TACTCTGGGTT and ligating into BN digested with BstBI and NdeI.
The mutant D2 was made by subcloning the second calcium binding
domain of aIIb into IIba5 using a subcloning and PCR strategy that
precisely transferred aIIb-(286–315) into IIba5.
Second calcium binding domain mutants YAVAA, LD, and LMD
were made using the dut-, ung- method after subcloning the cDNA into
M13mp18. YAVAA-LD, YAVAA-LMD, and LD-LMD were made by
using the appropriate second mutagenic oligonucleotide after isolating
the first mutant. YAVAA-LD-LMD was made by using the YAVAA and
LMD oligonucleotides simultaneously with the LD cDNA. The sequence
of the second calcium binding domain of the mutant constructs is shown
in Fig. 1B. The cDNAs were isolated from double-stranded M13mp18 by
digestion with EcoRI and subcloned into Bluescript KS. aIIb was sub-
cloned into the expression vector pcDNAI/AMP by digestion with EcoRV
and XbaI. aIIb was also transferred into pRc/CMV, an expression vector
containing the neo gene, by digesting the vector with HindIII, blunting
with Klenow, and digesting with XbaI. The vector was then ligated with
the EcoRV–XbaI fragment of aIIb. Mutant constructs were transferred
to the expression vectors by subcloning the NotI–NruI fragment of each
mutant into similarly digested aIIb. b3DE and b3DEG2069A were sub-
cloned into pcDNAI/Amp and pRc/CMV by digestion with EcoRV and
XbaI. The sequence of all clones was confirmed using dideoxy nucleotide
sequencing (49).
Cell Culture and Transfections—Chinese hamster ovary K1 (CHO)
cells were maintained and transfected as described previously (50).
COS-7 cells were maintained in DMEM supplemented with 10% FBS
and 1% penicillin and streptomycin. Wild type or mutant constructs
were co-transfected with b3DE into COS-7 cells using LipofectAMINE.
Cells were plated at 1.3 3 105 cells/cm2 in 25-cm2 flasks. One day after
plating, cells were washed with serum-free DMEM and incubated with
2.75 ml of serum-free DMEM and 0.5 ml of Opti-MEM I containing a
total of 2.5 mg of b3DE and aIIb construct, each in pcDNAI/Amp, and 24
1 The abbreviations used are: FBS, fetal bovine serum; CHO, Chinese
hamster ovary K1, DMEM, Dulbecco’s modified Eagle medium, high
glucose formula; PBS, phosphate-buffered saline; mAb, monoclonal an-
tibody; FITC, fluorescein isothiocyanate; BSA, bovine serum albumin;
DTT, dithiothreitol.
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ml of LipofectAMINE. After 5 h at 37 °C, 2.5 ml of DMEM containing
20% FBS was added. Twenty-four h later, the medium was replaced
with DMEM containing 10% FBS. Cells were assayed 72 h after the
start of transfection.
Flow Cytometry—Flow cytometry was performed as described previ-
ously (50) except that for PAC1 studies, cells were incubated with a
1:100 dilution of LIBS 6 ascites with or without 1 mM GRGDSP peptide
for 15 min at 37 °C. Cells were washed and stained with FITC-conju-
gated rabbit anti-mouse IgM. For studies of subunit dissociation, cells
were harvested and washed and then resuspended in PBS containing
2% BSA. Immediately before the start of the experiment, EDTA was
added to a final concentration of 5 mM. Cells were incubated at the
indicated temperature for the indicated times and then immediately
diluted 10-fold with PBS, centrifuged, and resuspended in PBC (PBS
containing 2% BSA, 0.1 mM CaCl2, and 0.1 mM MgCl2) containing the
aIIbb3 complex-specific mAb AP2 and processed as above.
Immunoprecipitation—Surface labeling and immunoprecipitation
were performed essentially as described previously (50).
Antibody Binding—One mg of mAb AP2 (IgG fraction) was iodinated
with 2 mCi of Na125I using 2 mM chloramine T for 5 min at 22 °C,
quenched with 2.3 mM Na2S2O5, and separated from free Na
125I by gel
filtration. Cells were harvested with EDTA and trypsin as described
above for flow cytometry and resuspended in Tris-buffered saline plus
0.5% BSA. Typically, 5 3 105 cells were incubated with varying concen-
trations of [125I]AP2 for 30 min at 22 °C in a total volume of 0.5 ml.
Triplicate 50-ml aliquots were layered over 0.4 ml of 20% sucrose, 0.5%
BSA in Tris-buffered saline and centrifuged at 12,000 3 g for 2 min. The
samples were aspirated to dryness, and the radioactivity associated
with the cell pellets was measured in a g-spectrometer. Total radioac-
tivity in the sample was determined by counting triplicate 50-ml ali-
quots of the reaction mixture. Nonspecific binding was defined as the
radioactivity associated with the cell pellets of mock-transfected cells
and was subtracted from that of aIIbb3-expressing cells. The data were
fit to equilibrium binding models (51).
Adhesion—Cells were harvested as above for flow cytometry and
resuspended in PBC. Flat bottomed immunoassay 96-well polystyrene
plates were incubated with either 2.5 mg/ml fibronectin or 4 mg/ml
fibrinogen in PBS for 16 h at 4 °C. Plates were then incubated with PBS
with 2% BSA for 2 h at 37 °C to block nonspecific binding sites on the
plates. Typically, 2 3 106 cells/ml were incubated with PBC or PBC plus
1 mM GRGDSP for 30 min at 22 °C prior to plating 1 3 105 cells/well.
Cells were allowed to adhere to the plates for 2 h at 37 °C. Plates were
washed three times with PBS to remove nonadherent cells. Adherent
cells were stained with 0.5% crystal violet in PBS containing 20%
methanol for 30 min at 22 °C. Excess dye was removed by three washes
with water, and cells were solubilized in 1% SDS for 16 h at 22 °C.
Adhesion was quantified by measuring the absorbance at 540 nm in a
BIO-TEK EL 340 microplate reader (BIO-TEK Instruments, Winooski,
VT). Nonspecific binding was defined as the absorbance of cells binding
to BSA-coated wells and was subtracted from the absorbance of cells
binding to ligand-coated wells. All assays were performed in triplicate.
Aggregation—All operations were performed at 22 °C. Cells were
harvested as above for flow cytometry and resuspended in HEPES-
Tyrode’s buffer, pH 7.5, at 2 3 107 cells/ml. Cells were incubated with
10 mM DTT for 20 min, pelleted, and resuspended at the same concen-
tration in HEPES-Tyrode’s buffer with or without inhibitors. Cells were
incubated for 30 min, and then CaCl2 was added to 0.4 mM. One
hundred ml of cells was placed in wells of a 48-well tissue culture plate
and incubated with or without 0.25 mg/ml fibrinogen for 30 min at 75
rpm on a gyrotory shaker. Cells were analyzed for aggregation by bright
field microscopy.
Fibrinogen Binding—Fibrinogen was passed over a gelatin-agarose
column two times to deplete the fibrinogen of fibronectin. Fibrinogen
and AP2 were labeled using FITC-Celite essentially as described by Xia
et al. (52). The fluorescein:protein ratio for fibrinogen ranged from 3 to
5, while the AP2 had a fluorescein:protein ratio of 3. Cells were har-
vested as above for flow cytometry and resuspended at a final concen-
tration of 3 3 106 cells/ml in DMEM containing 20 mM HEPES, pH 7.5,
LIBS 6 ascites at a 1:100 dilution, and either 0.25 mM ligand-blocking
peptide RGDW or buffer. Cells were incubated at room temperature for
15 min, and then FITC-fibrinogen was added at the indicated final
concentration. Cells were incubated for 30 min at room temperature,
washed with PBS, fixed with 1% paraformaldehyde in PBS at 4 °C, and
analyzed by flow cytometry. For both fibrinogen and AP2 binding,
cytometry was scrupulously gated to analyze only single cells. In an
effort to exclude cells lying outside the normal range, only the central
98% of the fluorescent signal (as determined by minimizing the coeffi-
cient of variance) was averaged to determine mean fluorescent inten-
sity. Specific binding was defined as the difference in mean fluorescent
intensity between cells incubated in the presence and absence of
RGDW. Data was fitted to the one-site ligand binding equation y 5
a0 * x/(a1 1 x) using the iterative nonlinear curve fitting function of
SlideWrite® Plus (Advanced Graphics Software, Inc., Carlsbad, CA).
To test the effect of the anti-N-terminal and anti-C-terminal fibrin-
ogen Aa RGD motif and anti-g-chain antibodies, cells were resuspended
in HEPES-Tyrode’s buffer without calcium or magnesium that had
been treated with Chelex 100. Cells were incubated with 2 mM Ca21 and
LIBS 6 or with 1 mM Mn21 in the presence or absence of 1 mM GRGDSP
for 15 min at 22 °C. Fibrinogen and control or anti-fibrinogen peptide
IgG were added to final concentrations of 50 nM and 10 mg/ml, respec-
tively. Cells were incubated at 22 °C for 30 min, washed with HEPES-
Tyrode’s buffer, and then incubated at 22 °C for 30 min with a 1:10
dilution of FITC-chicken anti-human fibrinogen in HEPES-Tyrode’s
buffer. Cells were washed, fixed, and analyzed by flow cytometry as
above.
RESULTS
Expression of Mutant Constructs—To determine if the vari-
ous aIIb calcium binding domain mutants were expressed on
the cell surface, CHO cells co-transfected with the mutants and
wild type b3 were analyzed by flow cytometry using Tab, a
murine monoclonal antibody that binds aIIb. As shown in Fig.
2, all of the constructs with point mutations in the second
calcium binding domain, including YAVAA-LD-LMD in which
the entire second calcium binding domain of aIIb was replaced
by the equivalent sequence in a5, were recognized by Tab,
which indicated cell surface expression of the mutant subunit.
Similar studies also showed that these mutants were recog-
nized by complex-specific antibodies 10E5, AP2, and A2A9,
suggesting complex formation with b3 (data not shown). Immu-
noprecipitation with anti-b1 and anti-b3 mAbs confirmed that
each of the aIIb chimeras complexed with b3 and not b1 (data
not shown). Radiolabeled antibody binding studies determined
that each cell line expressed approximately 150,000 AP2 sites/
cell (range 71,000–182,000) with the same dissociation con-
stant, Kd, as reported for AP2 binding to platelets (38) (data not
shown).
In contrast, more extended chimeras such as IIba5, a chi-
mera in which the entire calcium binding domain of aIIb was
FIG. 1. A, schematic representation of IIba5, D2, and DCa mutants.
The position of the start and stop of the calcium binding domains of aIIb
is indicated. Boxes show calcium binding domains. Black, aIIb sequence;
gray, a5 sequence. B, sequence of second calcium binding domain mu-
tants. Underlined, boldface amino acids were mutated from aIIb to a5
sequence; double underlined amino acids indicate calcium liganding
sites.
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replaced with the corresponding sequence of a5, and D2, a
chimera in which the first, third, and fourth calcium binding
domains of aIIb were replaced by the corresponding sequences
of a5, were not recognized by flow cytometric analysis with any
anti-aIIb or complex-specific antibody tested (data not shown),
indicating lack of expression on the cell surface. Likewise, DCa,
an in-frame deletion mutant in which the entire calcium bind-
ing domain was removed, was not expressed on the cell surface.
To examine further the synthetic defect in IIba5, D2, and
DCa, the mutant proteins were transiently expressed in COS-7
cells with b3 and analyzed by immunoprecipitation of cell ly-
sates using the mAb B1B5. B1B5 recognizes an epitope near
the transmembrane region of aIIb (42), an area that should not
be disturbed by the mutations. When cell surface proteins were
labeled with biotin prior to cell lysis and immunoprecipitation,
cells transfected with the mutant constructs had very faint
bands corresponding to mature aIIb and b3, confirming the flow
cytometry data suggesting little or no surface expression of the
chimeric complexes (Fig. 3 and data not shown). Analysis of
immunoprecipitates of unlabeled cell lysates revealed that cells
transfected with the mutants synthesized single chain precur-
sors and a small amount of mature aIIb-like proteins, but the
molecular weight of each of the mutant aIIb proteins was dif-
ferent from wild type aIIb (Fig. 3). DCa was smaller than aIIb, as
expected from a protein with a 204-amino acid deletion, while
IIba5 and D2 were both slightly larger than aIIb. Both of these
chimeras contain a5 sequence from the start of the calcium
binding domains up to the second calcium binding domain and
include the amino acid sequences NLT, NGS, and NFS, all
potential sites for N-linked glycosylation. Thus, the increased
molecular weight of IIba5 and D2 compared with wild type aIIb
might be attributed to increased glycosylation.
Adhesion Studies—The adherence of mutant aIIbb3-express-
ing CHO cells to fibronectin or fibrinogen immobilized on the
wells of microtiter plates was examined. Resting platelets can
bind to fibrinogen-coated surfaces; the aIIbb3 complex does not
have to assume an activated conformation to bind to solid
phase fibrinogen (53). As shown in Fig. 4, all of the cell lines
bound to fibronectin-coated wells as the result of constitutive
expression of the a5b1 fibronectin receptor. Cells expressing
wild type aIIbb3 also bound to fibrinogen, and the binding could
be blocked by preincubation with the RGD peptide GRGDSP,
but not by GRGESP. When we examined the ligand binding
capabilities of the mutants, all of the second calcium binding
domain chimeras bound to both fibronectin and fibrinogen, and
fibrinogen binding was blocked by GRGDSP or by 250 mg/ml
AP2 (data not shown) but not by GRGESP (data not shown).
For each cell line, there was day to day variation in binding to
the ligands, but the ratio of cells binding to fibrinogen versus
fibronectin remained constant. Recently, Suehiro and co-work-
ers reported that immobilized fibrinogen is a ligand for a5b1 in
the presence of calcium (54); yet in our studies, cell lines that
did not express aIIbb3 did not bind to fibrinogen, and binding to
fibrinogen was blocked by aIIbb3-specific mAbs, indicating that
all fibrinogen binding was to aIIbb3, not a5b1.
Activation Studies—CHO cells expressing wild type aIIbb3 do
not respond to normal platelet agonists, including thrombin,
FIG. 2. Detection of second calcium binding domain recombi-
nant heterodimers on the cell surface of stably transfected
CHO cells. Cells were incubated with Tab, a mAb against aIIb,
washed, and stained with FITC-labeled goat anti-mouse IgG. Cells
were analyzed by flow cytometry. Open curve, mock-transfected cells;
filled curves, named cells. b3, cells transfected with b3 only. All other
cell lines were co-transfected with the indicated aIIb construct and b3.
aIIb, wild type aIIbb3; Y-LD, YAVAA-LD; Y-LMD, YAVAA-LMD; Y-L-L,
YAVAA-LD-LMD.
FIG. 3. IIba5, D2, and DCa are synthesized but not expressed
on the cell surface of transiently transfected COS cells. Cell
lysates were immunoprecipitated with B1B5, a mAb to aIIb that binds
distal to the mutated region. The proteins were separated on 7.5% gels
under reducing conditions and transferred to nitrocellulose. Left, pro-
teins immunodetected with SEW 8, a polyclonal antibody to aIIb. Right,
lysates from cells that had been surface-labeled with biotin detected
with streptavidin-horseradish peroxidase chemiluminescence. PLT,
platelet lysate. In both panels the top arrow indicates aIIba. In the right
panel, the middle arrow indicates b3, and the lower arrow indicates
aIIbb. IIIa, cells transfected with b3 only; DCa, cells transfected with
aIIbDCab3; IIb, cells transfected with wild type aIIbb3; IIba5, cells trans-
fected with aIIba5b3.
FIG. 4. CHO cells expressing chimeric second calcium binding
domain heterodimers adhere to ligand-coated plates. Microtiter
plates were coated overnight with fibronectin or fibrinogen. Nonspecific
binding sites were blocked with BSA. Cells were allowed to attach to the
plate for 2 h and washed, and the number of cells that bound were
quantified by staining with methylene blue and subtracting nonspecific
binding (binding to BSA). Black bars, adherence to fibronectin; cross-
hatched bars, adherence to fibrinogen; gray bars, cells were incubated
with 1 mM GRGDSP for 30 min before plating onto fibrinogen-coated
wells. M, mock; b3, cells transfected with b3 only. All other cells were
transfected with b3 and the indicated a-subunit. IIb, cells transfected
with wild type aIIb; Y, YAVAA; Y-LD, YAVAA-LD; Y-LMD, YAVAA-LD-
LMD; L-L, LD-LMD; Y-L-L, YAVAA-LD-LMD.
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phorbol myristate acetate, or epinephrine, to yield an active
aIIbb3 complex, presumably because the cells do not possess the
necessary functional signaling pathways. However, aIIbb3 ex-
pressed on the surface of platelets can be induced to assume an
active conformation by treatment with the disulfide bond re-
ducing agent DTT (55, 56). Cells were incubated with DTT for
20 min at room temperature, washed, and then incubated with
soluble fibrinogen for 30 min at room temperature with stir-
ring. Under these conditions, cells expressing aIIbb3 formed
large aggregates (Fig. 5). Aggregation was dependent on DTT
treatment, since untreated cells expressing aIIbb3 did not ag-
gregate upon incubation with fibrinogen (data not shown). Ag-
gregation could be inhibited by preincubation of the DTT-
treated cells with the peptide inhibitor GRGDSP, H12, or 80
mg/ml aIIbb3 complex-specific mAb A2A9 but not by preincuba-
tion with GRGESP or irrelevant antibody (data not shown).
Cells expressing b3 only did not aggregate when treated with
DTT prior to incubation with fibrinogen (data not shown). As
shown in Fig. 5, each of the second calcium binding domain
mutants aggregated in the same manner as did cells expressing
wild type aIIbb3, indicating that each of the mutants main-
tained the ability to bind fibrinogen, despite the introduction of
a5 sequence.
Similar results were obtained when the mutant second cal-
cium binding domain chimeras were activated using the an-
ti-b3 mAb LIBS 6, and activation was detected using PAC1, a
ligand mimetic antibody that recognizes only the active confor-
mation of aIIbb3. Mock-transfected cells or those transfected
with b3 alone showed a minimal amount of PAC1 binding. Cells
expressing wild type or each of the mutant aIIbb3 heterodimers
showed significant PAC1 binding after activation with LIBS 6
(Fig. 6). For each cell line, PAC1 binding was inhibited by
incubation with GRGDSP (data not shown).
Since the aggregation studies used high concentrations of
fibrinogen (750 nM), well above the reported Kd of 60 and 110
nM for aIIbb3 expressed in tissue culture cells (22, 57), we
examined the possibility that more subtle changes in fibrino-
gen binding were caused by the various chimeras. Soluble
fibrinogen binding was carried out for each chimeric cell line at
two fibrinogen concentrations, one above and one below the
reported range for the Kd. Cells were activated with LIBS 6
antibody and incubated with FITC-fibrinogen in the presence
or absence of RGDW blocking peptide and analyzed by flow
cytometry (data not shown). Fibrinogen binding was dependent
on activation of aIIbb3, since cells incubated with FITC-fibrin-
ogen but without LIBS 6 did not exhibit any specific binding.
Mock-transfected cells and cells expressing only b3 did not bind
FITC-fibrinogen either before or after incubation with LIBS 6,
indicating that measurable soluble fibrinogen binding was oc-
curring only through binding to aIIbb3. Each of the cell lines
bound soluble fibrinogen at both ligand concentrations. How-
ever, when normalized for cell receptor number, some differ-
ences in FITC-fibrinogen binding were apparent. To determine
if the differences were indicative of changes in either Kd or
maximal binding (Bmax), full equilibrium binding isotherms
were performed on wild type cells and YAVAA and LD, the
mutants with the most widely divergent binding at the two
concentrations tested. Full binding isotherms revealed no dif-
ference in the Kd of YAVAA compared with wild type aIIbb3
(300 6 50 nM for wild type aIIbb3 versus 280 6 82 nM for YAVAA
(Fig. 7). The maximal fibrinogen binding of YAVAA, however,
was only 44 6 5% that of wild type aIIbb3 (p , 0.001). LD, on
the other hand, demonstrated a somewhat reduced Kd of 110 6
34 nM (p , 0.005) with a slightly increased Bmax of 120 6 11%
of wild type aIIbb3. The observed differences in binding param-
eters were small but reproducible over multiple experiments
using several lots of FITC-fibrinogen.
Suehiro et al. (54) have reported that soluble fibrinogen can
bind to a5b1 in the presence of manganese but not calcium.
Binding was shown to be mediated by the C-terminal Aa RGD
sequence of fibrinogen by inhibition of fibrinogen binding with
an antibody to this region but not with antibodies to either the
N-terminal Aa RGD sequence or the g-chain H12 sequence. To
look for a potential difference in fibrinogen binding mechanism
by the chimeric mutants, fibrinogen binding to wild type or
YAVAA-LD-LMD, which substitutes the complete second cal-
cium binding domain of a5 into aIIb, was examined in the
presence of calcium or manganese, and inhibition of this bind-
ing with antibodies against the fibrinogen N- or C-terminal Aa
RGD sequences or the g-chain H12 sequence was determined.
As shown in Fig. 8, neither the N- nor C-terminal Aa RGD
sequence antibodies inhibited fibrinogen binding in the pres-
ence of either calcium or manganese, while the anti-g-chain
H12 antibody significantly inhibited soluble fibrinogen binding
to both wild type (71% inhibition in calcium and 77% in man-
ganese) and YAVAA-LD-LMD (81% in calcium and 80% in
manganese), demonstrating that even when the second calcium
binding domain of aIIb is replaced with the second calcium
binding domain of a5, binding of soluble fibrinogen is mediated
by the g-chain H12 sequence.
Dissociation Studies—When platelets are incubated at 37° C
with EDTA at alkaline pH, the aIIbb3 complex irreversibly
dissociates, and this subunit dissociation can be monitored by
loss of binding of the complex-specific antibody AP2 (58). We
looked for changes in the stability of the mutant aIIbb3 com-
plexes by incubating CHO cells expressing the complexes with
5 mM EDTA at pH 7.4 at varying temperatures. No loss of AP2
binding to wild type aIIbb3 or any of the mutants occurred when
the cells were incubated at 22° C for 1 h (data not shown).
When wild type and mutant cells were incubated at 37° C, the
complexes dissociated at different rates, as seen in Fig. 9. Wild
type aIIbb3 complex dissociation occurred with a half-time of
FIG. 5. Aggregation of CHO cells expressing chimeric second
calcium binding domain heterodimers. Cells were incubated with
10 mM DTT for 20 min, washed, and incubated with buffer (2Fg) or 750
nM fibrinogen (1Fg) with agitation at 80 rpm, fixed with paraformal-
dehyde, and analyzed using bright field microscopy. IIb, wild type aIIb;
Y, YAVAA; Y-LD, YAVAA-LD; Y-LMD, YAVAA-LMD; Y-L-L,
YAVAA-LD-LMD.
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2.56 6 0.07 min. YAVAA dissociated much faster, with a half-
time of 0.82 6 0.04 min, while LD was more stable, having a
dissociation half-time of 3.73 6 0.09 min. YAVAA-LD-LMD,
which contains the complete a5 second calcium binding do-
main, had a dissociation half-time of 2.19 6 0.06 min, which is
not statistically different from that of wild type aIIbb3. When
the cells were incubated with EDTA at 41° C, wild type and
mutant aIIbb3 complexes dissociated more rapidly than at
37° C but in the same rank order: YAVAA less stable than
YAVAA-LD-LMD and wild type, which were less stable than
LD (data not shown). When the cells were incubated with
EDTA at temperatures below 37° C, only YAVAA showed a
significant loss of AP2 binding (data not shown). Thus, there
appears to be a correlation between complex stability and fi-
brinogen binding. For example, YAVAA was less stable than
wild type aIIbb3 and YAVAA-LD-LMD when incubated with
EDTA and exhibited decreased maximal fibrinogen binding,
while LD was more stable than wild type aIIbb3 and YAVAA-
LD-LMD and had an increased affinity for fibrinogen.
DISCUSSION
The major findings of this study are as follows. 1) Chimeric
aIIb containing the four calcium binding domains of a5; contain-
ing domains 1, 3, and 4 of a5; or deleted of calcium binding
domains is synthesized but is neither processed nor expressed
FIG. 6. Binding of PAC1 to second calcium binding domain recombinant heterodimers on the cell surface of stably transfected
CHO cells. Cells were incubated with buffer (open curves) or activating anti-b3 mAb LIBS 6 (filled curves). Cells were then incubated with PAC1
followed by FITC-rabbit anti-mouse IgM. Cells were analyzed by flow cytometry. b3, cells transfected with b3 only. All other cell lines were
transfected with b3 and the indicated a-subunit. aIIb, wild type aIIb; Y-LD, YAVAA-LD; Y-LMD, YAVAA-LMD; Y-L-L, YAVAA-LD-LMD.
FIG. 7. Mutant cell lines YAVAA and LD bind fibrinogen with
properties similar to CHO cell expressing wild type aIIbb3. Spe-
cific binding of fibrinogen was measured by incubating cells with LIBS
6-activating antibody either in the presence or absence of 0.25 mM
ligand-blocking peptide RGDW. FITC-fibrinogen was added at the in-
dicated final concentration, and cells were incubated for 30 min at
22 °C, washed, fixed, and analyzed by flow cytometry. Specific binding
was defined as FITC-fibrinogen binding minus FITC-fibrinogen binding
in the presence of RGDW. Binding was normalized for differences in
receptor number by determining the relative receptor number in the
different mutants as compared with wild type by binding of the complex
specific mAb AP2 that had been directly labeled with FITC. Maximum
binding to wild type was set at 1. The results are the average of three
(LD) or four (wild type and YAVAA) determinations. l, wild type; M,
YAVAA; ‚, LD.
FIG. 8. Inhibition of fibrinogen binding by anti-fibrinogen an-
tibodies. Cells were incubated with 2 mM Ca21 and LIBS 6 or with 1
mM Mn21, as indicated, in the presence or absence of 1 mM GRGDSP for
15 min at 22° C. Fibrinogen and control or anti-fibrinogen peptide IgG
were added to a final concentrations of 50 nM and 10 mg/ml, respec-
tively, and cells were incubated for 30 min at 22° C, washed, and then
incubated with FITC-chicken anti-human fibrinogen IgG for 30 min at
22° C, washed, fixed, and analyzed by flow cytometry. Specific binding
was defined as fibrinogen binding minus fibrinogen binding in the
presence of GRGDSP. Specific fibrinogen binding in the presence of
control IgG was set at 100. The results are expressed as the mean 6
S.E. of three independent experiments. WT, wild type; YLL, YAVAA-
LD-LMD. Black bar, control IgG; narrow diagonal bar, anti-Aa chain
N-terminal RGD IgG; wide diagonal bar, anti-Aa chain C-terminal
RGD IgG; cross-hatched bar, anti-g chain H12 IgG. Inhibition by the
anti-g-chain H12 IgG was significantly different from control IgG
(p , 0.001) in all cases.
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on the cell surface. 2) Chimeras containing subsets or all of the
variant amino acids of the second calcium binding domain of a5
are synthesized, complexed with b3, processed, and expressed
on the cell surface, and they retain epitopes of aIIb and aIIbb3.
3) Second calcium binding domain chimeras retain the func-
tions of adhesion to fibrinogen, binding of the ligand mimetic
antibody PAC 1, binding soluble fibrinogen, and fibrinogen-de-
pendent aggregation. 4) Second calcium binding domain chime-
ras bind fibrinogen utilizing the g-chain H12 sequence as op-
posed to the C-terminal Aa RGD sequence that is used in
fibrinogen binding to a5b1. 5) Changes in the amino acid se-
quence of the second calcium domain have varying effects on
subunit stability.
The fundamental observation of this study, that the chimeric
second binding domain aIIba5b3 proteins were capable of bind-
ing fibrinogen as evidenced by soluble fibrinogen binding stud-
ies and aggregation of CHO cells expressing these proteins
after activation with either LIBS 6 activating antibody or DTT
and incubation with fibrinogen, conflicts with a number of
previously published works, which indicate that amino acids
291–314 are important for ligand binding. D’Souza and co-
workers (30) demonstrated that aIIb-(296–306) inhibited
125I-
labeled fibrinogen binding to platelets, but a peptide with the
conservative mutation D301E was a much less potent inhibitor.
They also found that neither the a5 nor av homologs of aIIb-
(296–306) inhibited binding of fibrinogen to purified aIIbb3,
while aIIb-(296–306) did (36). Taylor and Gartner (33) reported
that aIIb-(300–312) blocked adhesion of platelets to fibrinogen,
fibronectin, and vitronectin, while the av homolog would par-
tially block platelet adhesion to vitronectin but not fibrinogen
or fibronectin. Furthermore, the results of our experiments are
surprising in light of recent NMR studies by Yao and Mayo
(59), who suggested that both hydrophobic amino acids and the
positively charged arginine and histidine residues play a sig-
nificant role in binding of aIIb-(300–314) to fibrinogen. They
concluded that the RHDLL and PLYM sequences in that pep-
tide have the strongest interaction with fibrinogen, yet the
mutations that we made in these sequences, RHDLL 3 LD-
DLL and PLYM 3 PLLM, did not significantly change the
fibrinogen binding functionality, either by themselves or to-
gether in the chimeric protein complexes.
Our data demonstrate that all of the chimeric mutants bound
soluble fibrinogen at concentrations as low as 25 nM; however,
some small, but statistically significant alterations in ligand
binding appear to be present, especially for YAVAA and LD.
YAVAA exhibited a Bmax value less than half that of wild type
aIIbb3, possibly caused by a molecular structure that may have
been more resistant to activation by LIBS 6. LD, with mutation
of one of the calcium liganding amino acids and a 22 change in
ionic charge, exhibited only a modest, 3-fold increase in affinity
for fibrinogen. Overall, the data suggest that the chimeras with
mutations in the second calcium binding domain may have
some structural differences affecting aIIbb3 complex stability,
as evidenced by the altered EDTA dissociation profiles, but the
chimeras do not exhibit major changes in either the specificity
of fibrinogen binding or the amino acid sequence in fibrinogen
required for binding.
A possible interpretation of the results is that the second
calcium binding domain is important for ligand binding, but
only in the sense that it must be present in a conformation that
supports binding of divalent cation. Calcium (or magnesium)
binding is required for not only subunit association, but for
allowing the receptor to be in a conformation that supports
ligand binding (60). Substituting the second calcium binding
domain of a5 into aIIb should still allow formation of a divalent
cation binding loop, since the oxygenated residues that provide
calcium coordination sites were not mutated. Interestingly, one
coordination site was changed, an Arg in aIIb to a Leu in a5.
However, calcium coordination at this site is predicted to be
through the main-chain carbonyl, based on the model of the
calmodulin EF-hand structure (34). Thus, the amino acid dif-
ferences between aIIb and a5 may produce subtle differences in
the second calcium binding domain but differences that still
support calcium and, therefore, ligand binding. Less conserva-
tive mutations to residues involved in calcium binding demon-
strate the importance of the integrity of the loop structure for
ligand binding. Masumoto and Hemler (61) performed alanine-
scanning mutagenesis on the metal ion binding residues of the
first divalent cation binding domain of a4 and found that mu-
tant protein complexes were not expressed on the cell surface.
Only the conservative change of Glu for Asn or Asp at the third
coordination site of any one of the divalent cation binding
domains resulted in surface expression, and the mutant pro-
teins exhibited decreased ligand binding. We have performed
alanine-scanning mutagenesis and made more conservative
mutations to the calcium-liganding residues in the second cal-
cium binding domain of aIIb and found that although the mu-
tated aIIb subunits were synthesized and were able to complex
with b3, they were not properly processed, and the complexes
were not expressed on the cell surface.2
Another interpretation of the results is that the second cal-
cium binding domain is required for ligand binding (i.e. it
interacts with RGD, but the specificity of ligand binding resides
in sequences that flank the second calcium binding domain).
While the calcium binding domains, DXDXDGXXD, are highly
conserved, occurring near the middle of an FG . . . (DXDX-
DGXXD) . . . GAP . . . GXXY conserved N-terminal repeat, the
sequence outside the FG . . . GXXY sequence is very poorly
conserved among integrins (35). Even the sequence between
the GAP and GXXY sequences of the second calcium binding
domains of aIIb and a5 is poorly conserved, differing at 9 of 14
amino acids. Several groups have demonstrated the impor-
tance of sequence flanking the RGD, RYD, or KGD recognition
sequence of disintegrins in determining binding specificity (62–
64). Kunicki and co-workers (65) have demonstrated the im-
portance of flanking amino acids in experiments where the
amino acids surrounding the RGD tripeptide in the Fab ligands
PAC1.1 and AP7, not the RGD binding sequence itself, deter-
mined whether ligand binding was activation-sensitive. Flank-
ing sequences have been shown to be important in determining
ligand binding specificity for many receptors and enzymes in-
2 S. Gidwitz and G. C. White II, manuscript in preparation.
FIG. 9. Loss of complex-specific antibody binding after incu-
bation with EDTA at 37° C. Cells were incubated with 5 mM EDTA at
37° C for the indicated time, washed, incubated with AP2, washed,
incubated with FITC-goat anti-mouse IgG, washed, fixed, and then
analyzed by flow cytometry. Each curve is the average of four separate
experiments. f, wild type (WT); l, YAVAA (Y); Œ, LD; l, YAVAA-LD-
LMD (YLL); ns, not significant.
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cluding Src homology 2 and 3 domains, T-cell receptors, Kit,
and a-glucan phosphorylase (66–70).
Recently, a new model for the N-terminal 440 amino acids of
a-integrins was proposed (71). The seven FG . . . GAP repeats
were predicted to form a seven-membered b-propeller similar
to that formed by the b-subunit of heterotrimeric G proteins.
Ligand binding was suggested to occur in a pocket on the upper
surface of the b-propeller. In contrast, the calcium binding
loops are modeled on the lower surface of the propeller, poten-
tially in contact with the b-subunit. Thus, mutation of RH 3
LD at amino acids 302–303 in the second calcium binding loop
would be predicted to be on the lower surface of the propeller
and away from the ligand binding pocket. In contrast, His291 is
suggested to be one of the residues lining the ligand binding
pocket, as modeled on Gb, while Tyr313 and Glu315 would be
predicted to be in a loop that lies on the upper surface of the
protein. If this model is correct, mutation of these residues to
the corresponding a5 sequence might be expected to change
ligand binding specificity. Mutations at any of these residues,
however, did not change ligand binding specificity for fibrino-
gen and had only small effects the Kd or Bmax, suggesting that
either these residues are not critical for ligand binding or that
the mutations were conservative enough to allow ligand
binding.
A potential explanation for the differences between the pep-
tide studies and our results is that the second calcium binding
domain of the chimeric constructs is constrained into a confor-
mation that allows ligand binding, while the more highly mo-
bile free peptides adopt conformations that may or may not
block ligand binding. The wild type aIIb peptide may reside in
a conformation that blocks ligand binding, while a blocking
conformation for the mutant aIIb or wild type a5 or av peptides
may be thermodynamically unfavored. The effect of constrain-
ing a peptide structure has been demonstrated in studies with
cyclic versus linear RGD peptides, where cyclization increases
the affinity and specificity of the peptide for individual inte-
grins (72, 73).
Three areas of aIIbb3 have been implicated in binding of the
C terminus of the g-chain of fibrinogen. Two are in aIIb, amino
acids 294–312 and 656–667 (29–33). Alemany (24) and co-
workers have presented evidence that b3-(274–368) may also
be involved. The properties of the implicated sites have some
similarities and some striking differences. aIIb-(294–312) has
been demonstrated to be the cross-linking site for the H12
peptide. It binds fibrinogen in a calcium-dependent manner,
and RGD peptides can compete for H12 binding (30). The site is
not exposed on the resting aIIbb3 complex. These properties
mimic the way fibrinogen interacts with aIIbb3 in vivo. The
second calcium binding domain chimeras interact with fibrin-
ogen in a similar fashion. aIIb-(656–667) also binds fibrinogen
with high affinity, but in a calcium-independent manner (29).
Binding can be partially blocked by H12 peptide, but not by
RGD, indicating a specificity for the g-chain. This site, too, is
cryptic on resting aIIbb3. The C-terminal g-chain-specific b3 site
at amino acids 274–368 is somewhat enigmatic in that soluble
fibrinogen binding is calcium-independent and the site is ex-
posed on both resting and activated aIIbb3 (24). Considering
that fibrinogen does not bind to resting platelets or to activated
platelets in the absence of calcium, it is unclear how this site
might function in vivo. Our data indicate that the fibrinogen
binding site is not exposed on the resting aIIbb3 or chimeric
complex and that RGD can inhibit the fibrinogen interactions,
suggesting that these later two sites are not involved in soluble
fibrinogen binding.
In conclusion, our data indicate that chimeras in which the
second calcium binding domain of aIIb is replaced by the corre-
sponding sequences of a5 retain the capacity to bind fibrinogen.
While one interpretation of this data is that the second calcium
binding domain is not involved in ligand binding, we speculate
that this region is important for ligation of the binding se-
quence(s) but that sequences outside the second calcium bind-
ing domain mediate ligand binding specificity.
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